Highest-materiality recent filing
28-day AN2-502998 treatment in NHPs with chronic T. cruzi infection achieved 100% parasite elimination at human-target exposures, durable for 4 months post-treatment.
AN2 Therapeutics enters $80M ATM offering with Jefferies; prior ATM terminated
Entered into Open Market Sale Agreement with Jefferies to sell up to $80M of common stock at market prices.
AN2 Therapeutics reports FY2025 net loss of $35.2M; $40M private placement extends runway into 2029
Net loss for FY2025 was $35.2 million, compared to $51.3 million in FY2024.
AN2 Therapeutics announces $40M private placement of common stock and pre-funded warrants
Gross proceeds ~$40M from sale of 8.25M shares at $2.85/share and 5.79M pre-funded warrants at $2.84999/warrant.
AN2 Therapeutics Q2 net loss narrows to $6.5M; Chagas Phase 1 dosing underway; cash runway into 2028
Net loss of $6.5M vs $14.4M in Q2 2024; R&D expenses down to $3.2M from $12.1M.
AN2 Therapeutics exchanges 2.8M common shares for pre-funded warrants with Coastlands Capital
Exchanged 2,500,000 shares of common stock for pre-funded warrant for 2,500,000 shares on June 17, 2025.
AN2 Therapeutics reports Q1 2025 net loss of $10.6M; cash runway extended to 2028
Net loss of $10.6M vs $16.6M in Q1 2024; R&D expenses down to $7.7M from $14.7M.
Phase 3 portion of EBO-301 (n=97) did not meet primary endpoint of QOL-B respiratory domain improvement at month 6.
AN2 Therapeutics reports FY2024 net loss $51.3M; Phase 3 epetraborole data expected 2Q25
Cash, equivalents, investments $88.6M at Dec 31, 2024; expected to fund operations through 2027.
AN2 Therapeutics reports Q3 2024 net loss $12.7M, positive Phase 2 epetraborole PRO data in TR-MAC
Net loss $12.7M in Q3 2024 vs $16.7M in Q3 2023; cash $93.4M, expected to fund operations through 2027.
AN2 Therapeutics adopts limited-duration stockholder rights plan after BML accumulates 19.3% stake
Rights plan triggered by rapid accumulation of 19.3% of ANTX common stock by BML Investment Partners, as disclosed in Aug. 14, 2024 13G/A filing.
Cash, equivalents, and investments $104.5M at June 30, 2024; runway through 2027.
AN2 discontinues EBO-301 MAC lung study, cuts ~50% workforce, shifts pipeline focus
Phase 2/3 EBO-301 study discontinued; sputum culture conversion at Month 6: 13.2% vs 10.0% (p=0.64).
AN2 Therapeutics Q1 net loss $16.6M; Phase 2 TR-MAC data expected August 2024
Net loss of $16.6M for Q1 2024 vs $15.3M in Q1 2023; cash $118.1M.
Net loss FY2023 $64.7M vs $41.0M prior year; Q4 net loss $16.9M vs $11.8M.
AN2 Therapeutics pauses Phase 3 enrollment in epetraborole trial after efficacy concern
Voluntary pause of Phase 3 enrollment in EBO-301 trial for treatment-refractory MAC lung disease.
AN2 Therapeutics Q3 net loss $16.7M; epetraborole Phase 3 enrollment underway
Net loss $16.7M for Q3 2023, up from $11.3M in Q3 2022; R&D and G&A expenses increased.
AN2 Therapeutics starts Phase 3 trial for epetraborole in refractory MAC lung disease
Phase 2 enrollment completed with 80 patients; topline Phase 2 data expected summer 2024.
AN2 Therapeutics prices $70M underwritten offering of 7.8M shares at $9.00
Underwritten offering of 7,777,778 shares at $9.00/share, gross proceeds ~$70M.
Net loss $15.8M for Q2 2023 vs $10.1M prior year; R&D expenses increased on clinical trial costs.
AN2 Therapeutics reports Q1 net loss of $15.3M; Phase 2/3 trial enrollment on track
Net loss of $15.3M for Q1 2023, compared to $7.7M in Q1 2022.
AN2 Therapeutics reports Q4 2022 net loss $11.8M, full year loss $41.0M; cash $99.3M
Net loss for Q4 2022 was $11.8M and full year 2022 was $41.0M.
AN2 Therapeutics Q3 2022: Cash $106.4M; ongoing epetraborole trial; NIAID contract up to $17.8M
Cash, cash equivalents and investments totaled $106.4M as of Sep 30, 2022; expected to fund operations through mid-2024.
Phase 1 study in Japanese volunteers (EBO-103) showed no adverse events, supports once-daily 500 mg dose for Phase 2/3.
AN2 screens first patient in pivotal Phase 2/3 trial of epetraborole for refractory MAC lung disease
Epetraborole is a once-daily oral therapy with novel MOA for treatment-refractory MAC lung disease, the most common NTM lung disease.
On November 4, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) appointed Joshua Eizen, the Company’s current Chief Legal Counsel, age 47, as Chief Legal Officer and Chief Operating Officer of the Company, effective immediately
Paul Eckburg, M.D., the Company’s Chief Medical Officer, will depart the Company effective as of August 30, 2024
On September 1, 2023, the Company’s Board of Directors appointed Lucy Day, the Company’s current Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer effective as of September 1, 2023.
The Company has hired Annie Yoshiyama, previously Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., as its new Vice President, Finance and Corporate Controller.
Michael Nazak, Vice President, Corporate Controller and the prior Principal Accounting Officer, will depart the Company effective September 15, 2023.
On May 5, 2022, Margaret (Maggie) M. FitzPatrick was appointed to the board of directors (the “ Board ”) of AN2 Therapeutics, Inc., a Delaware corporation (the “ Company ”), as a Class II Director
Max materiality 0.85 · Median 0.60 · Most common event other_material